Charles Schwab Investment Management Inc T Scan Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 22,104 shares of TCRX stock, worth $129,308. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,104
Previous 22,104
-0.0%
Holding current value
$129,308
Previous $128,000
36.72%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding TCRX
# of Institutions
67Shares Held
29.3MCall Options Held
0Put Options Held
0-
Eco R1 Capital, LLC San Francisco, CA5MShares$29.3 Million1.13% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.9MShares$22.8 Million0.06% of portfolio
-
Bvf Inc San Francisco, CA2.99MShares$17.5 Million0.71% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$16.3 Million0.28% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA2.09MShares$12.2 Million9.65% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $111M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...